Ono Pharmaceutical Financials
| OPHLY Stock | USD 3.59 0.09 2.45% |
Ono |
Please note, the imprecision that can be found in Ono Pharmaceutical's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Ono Pharmaceutical Co. Check Ono Pharmaceutical's Beneish M Score to see the likelihood of Ono Pharmaceutical's management manipulating its earnings.
Ono Pharmaceutical Stock Summary
Ono Pharmaceutical competes with Sanofi ADR, Bristol Myers, AstraZeneca PLC, Gilead Sciences, and Novartis. Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. The company was founded in 1717 and is headquartered in Osaka, Japan. Ono Pharmaceutical operates under Drug ManufacturersGeneral classification in the United States and is traded on OTC Exchange. It employs 3687 people.| Instrument | USA Pink Sheet View All |
| Exchange | PINK Exchange |
| ISIN | US6827361030 |
| Business Address | 8-2, Kyutaromachi 1-chome, |
| Sector | Healthcare |
| Industry | Drug Manufacturers—General |
| Benchmark | Dow Jones Industrial |
| Website | www.ono-pharma.com |
| Phone | 81 6 6263 5670 |
| Currency | USD - US Dollar |
Ono Pharmaceutical Key Financial Ratios
Ono Pharmaceutical's financial ratios allow both analysts and investors to convert raw data from Ono Pharmaceutical's financial statements into concise, actionable information that can be used to evaluate the performance of Ono Pharmaceutical over time and compare it to other companies across industries.Ono Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Ono Pharmaceutical's current stock value. Our valuation model uses many indicators to compare Ono Pharmaceutical value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Ono Pharmaceutical competition to find correlations between indicators driving Ono Pharmaceutical's intrinsic value. More Info.Ono Pharmaceutical Co is considered to be number one stock in return on equity category among its peers. It also is considered to be number one stock in return on asset category among its peers reporting about 0.75 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Ono Pharmaceutical Co is roughly 1.33 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Ono Pharmaceutical by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Ono Pharmaceutical's Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Ono Pharmaceutical Systematic Risk
Ono Pharmaceutical's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Ono Pharmaceutical volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Beta measures systematic risk based on how returns on Ono Pharmaceutical correlated with the market. If Beta is less than 0 Ono Pharmaceutical generally moves in the opposite direction as compared to the market. If Ono Pharmaceutical Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Ono Pharmaceutical is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Ono Pharmaceutical is generally in the same direction as the market. If Beta > 1 Ono Pharmaceutical moves generally in the same direction as, but more than the movement of the benchmark.
Ono Pharmaceutical December 14, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Ono Pharmaceutical help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Ono Pharmaceutical Co. We use our internally-developed statistical techniques to arrive at the intrinsic value of Ono Pharmaceutical Co based on widely used predictive technical indicators. In general, we focus on analyzing Ono Pink Sheet price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Ono Pharmaceutical's daily price indicators and compare them against related drivers.
| Information Ratio | (0.25) | |||
| Maximum Drawdown | 10.36 | |||
| Value At Risk | (2.42) | |||
| Potential Upside | 2.09 |
Additional Tools for Ono Pink Sheet Analysis
When running Ono Pharmaceutical's price analysis, check to measure Ono Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ono Pharmaceutical is operating at the current time. Most of Ono Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Ono Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ono Pharmaceutical's price. Additionally, you may evaluate how the addition of Ono Pharmaceutical to your portfolios can decrease your overall portfolio volatility.